Success Metrics

Clinical Success Rate
89.3%

Based on 25 completed trials

Completion Rate
89%(25/28)
Active Trials
3(7%)
Results Posted
64%(16 trials)
Terminated
3(7%)

Phase Distribution

Ph phase_3
9
20%
Ph not_applicable
4
9%
Ph phase_2
9
20%
Ph phase_4
17
39%
Ph phase_1
2
5%

Phase Distribution

2

Early Stage

9

Mid Stage

26

Late Stage

Phase Distribution41 total trials
Phase 1Safety & dosage
2(4.9%)
Phase 2Efficacy & side effects
9(22.0%)
Phase 3Large-scale testing
9(22.0%)
Phase 4Post-market surveillance
17(41.5%)
N/ANon-phased studies
4(9.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

25 of 30 finished

Non-Completion Rate

16.7%

5 ended early

Currently Active

3

trials recruiting

Total Trials

44

all time

Status Distribution
Active(5)
Completed(25)
Terminated(5)
Other(9)

Detailed Status

Completed25
unknown9
Terminated3
Recruiting2
Withdrawn2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
44
Active
3
Success Rate
89.3%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (4.9%)
Phase 29 (22.0%)
Phase 39 (22.0%)
Phase 417 (41.5%)
N/A4 (9.8%)

Trials by Status

not_yet_recruiting12%
active_not_recruiting12%
unknown920%
recruiting25%
enrolling_by_invitation12%
terminated37%
withdrawn25%
completed2557%

Recent Activity

Clinical Trials (44)

Showing 20 of 44 trialsScroll for more
NCT04886284Phase 2

Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia

Recruiting
NCT02041767Phase 4

Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration

Completed
NCT04502095Phase 4

Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy

Completed
NCT06920147Phase 4

PRevention Of Trauma-related Infections Through an Embedded Clinical Trials Network

Not Yet Recruiting
NCT05645757Phase 1

Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)

Completed
NCT03925402

Ertapenem for Initial Empirical Treatment of Third Generation Cephalosporin Resistant Enterobacteriaceae Bacteremia

Completed
NCT02729116Phase 2

Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients

Unknown
NCT03218800Phase 3

Ertapenem Administered Subcutaneously Versus Intravenously

Terminated
NCT03788967Phase 3

Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

Completed
NCT05255575

A Single Center, Prospective Clinical Trial of Intravenous Ertapenem in the Treatment of Hurley Stage II or III Hidradenitis Suppurativa

Withdrawn
NCT01844856Phase 3

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections

Completed
NCT03032510Phase 3

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections

Completed
NCT01265784Phase 2

Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections

Completed
NCT03357614Phase 3

Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults

Completed
NCT03358576Phase 3

Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)

Completed
NCT03236961Not Applicable

Optimizing the Antibiotic Treatment of Uncomplicated Acute Appendicitis

Active Not Recruiting
NCT03234296Not Applicable

Antibiotics vs. Placebo in Acute Uncomplicated Appendicitis

Enrolling By Invitation
NCT04505683Phase 2

A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

Completed
NCT04140578Phase 4

Antibiotic Prophylaxis in Patients Undergoing GVO

Recruiting
NCT02159859Phase 2

Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients

Completed

Drug Details

Intervention Type
DRUG
Total Trials
44